Obeldesivir clinical trials
Also written GS-5245.
Its developmentBy Gilead Sciences, step by step6 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses obeldesivir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses obeldesivir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) InfectionTerminatedPhase 2Gilead SciencesNCT06585150Written as ObeldesivirHow we know
- Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) InfectionTerminatedPhase 2Gilead SciencesNCT06784973Written as ObeldesivirHow we know
- Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus DiseaseWithdrawnPhase 2Gilead SciencesNCT06682234Written as obeldesivirHow we know
- Study of Obeldesivir in Children and Adolescents With COVID-19TerminatedPhase 2/3Gilead SciencesNCT05996744Written as ObeldesivirHow we know
- Study of Obeldesivir in Nonhospitalized Participants With COVID-19CompletedPhase 3Gilead SciencesNCT05715528Written as ObeldesivirHow we know
- Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe IllnessTerminatedPhase 3Gilead SciencesNCT05603143Written as ObeldesivirHow we know
Codes
What other systems call obeldesivir · ClinicalTrials.gg INT017644
- UNII (FDA) Q55KCM7PXBOBELDESIVIRConfirmed FDA, Wikidata
- Wikidata Q115859634obeldesivirConfirmed FDA, Wikidata
- NCI Thesaurus C190480ObeldesivirOne source FDA
- DrugBank DB18821One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Q55KCM7PXB | OBELDESIVIR | Confirmed FDA, Wikidata |
| Wikidata | Q115859634 | obeldesivir | Confirmed FDA, Wikidata |
| NCI Thesaurus | C190480 | Obeldesivir | One source FDA |
| DrugBank | DB18821 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.